NIW LAW FIRM

Law Office of Hong-min Jun · Chicago · Indianapolis

Menu
Healthcare / STEMApproved

Dr. S.K.

Drug Development Specialist

Pharmaceutical Sciences & Oncology · South Korea

Decision
Approved
Processing Time
7 months
RFE Received
None
Visa Category
NIW EB-2

Case Background

Dr. S.K. is a senior research scientist with a Ph.D. in Pharmaceutical Sciences from Seoul National University, specializing in oncology drug formulation. She had been conducting cutting-edge research at a top-20 U.S. pharmaceutical company for over 6 years, contributing to two FDA-approved cancer therapies. Her work focused on improving drug bioavailability for solid tumor treatment, directly impacting patient survival rates.

Strategic Challenge

The primary challenge was demonstrating that her work had national importance beyond the pharmaceutical company's commercial interests. Reviewers at USCIS often scrutinize drug development cases to ensure the benefit extends to the broader U.S. population, not just the employer.

Strategic Argument (Dhanasar Framework)

01

Prong 1: Substantial Merit

Her research directly addressed a critical gap in oncology treatment: low bioavailability of oral cancer drugs leads to higher dosages, greater toxicity, and reduced patient compliance. Her formulation innovations improved efficacy by 40%, with measurable patient outcome improvements documented in clinical trial data.

02

Prong 2: National Importance

Cancer is the second leading cause of death in the U.S., with over 1.9 million new diagnoses annually per NCI data. Her work was cited in FDA regulatory submissions and aligned with the National Cancer Institute's strategic research priorities for improving oral chemotherapy accessibility.

03

Prong 3: Waiver Justified

Her employer could not be the petitioner under normal PERM due to competitive hiring concerns. Her research was time-sensitive — a delay in labor certification would set back clinical trial timelines by 18-24 months, jeopardizing the national benefit of her ongoing contributions.

Key Evidence Submitted

  • 01
    14 peer-reviewed publications in journals including Journal of Controlled Release and Cancer Research (cumulative h-index: 18)
  • 02
    Inventor on 3 U.S. patents related to nanoparticle drug delivery systems for oncology
  • 03
    Expert recommendation letters from NCI-funded researchers and FDA advisory board members
  • 04
    Clinical trial documentation showing 40% improvement in drug bioavailability attributed to her formulations
  • 05
    Evidence of FDA fast-track designation for two therapies she contributed to developing
  • 06
    Citation analysis showing 280+ citations from international oncology researchers

Attorney Insights

This case succeeded because we shifted the narrative from "pharmaceutical company research" to "national public health infrastructure." By anchoring every argument to NCI priorities and FDA fast-track designations, we demonstrated that Dr. S.K.'s work had national importance independent of her employer. Expert letters from NCI-funded researchers — not just industry colleagues — were pivotal in establishing credibility.

Approval Documentation

USCIS Approval Notice

Client identity redacted for confidentiality

Case Summary

Petitioner
Dr. S.K.
Country of Origin
South Korea
Field
Pharmaceutical Sciences & Oncology
Visa Type
NIW (EB-2)
Processing Time
7 months (Premium)
Outcome
Approved — No RFE

Have a Similar Case?

Attorney Hong-min Jun can evaluate whether your background qualifies for NIW under the Dhanasar framework.

Request Free Consultation
Back to All Case Studies

Ready to Build Your NIW Strategy?

Every successful NIW case starts with a strategic assessment. Attorney Hong-min Jun will analyze your background against the Dhanasar framework and identify the strongest evidence for your petition.

Schedule Your Consultation
Talk with Us